- Organizations: SpyGlass Pharma, Inc
Pipeline
SpyGlass Pharma reports 4-year, FIH data on BIM-IOL System
Company is continuing phase 3 enrollment while working with the FDA toward a future NDA submission.Research
SpyGlass Pharma unveils positive 12-month data on BIM-IOL System
Interim findings offer a closer look at the safety and efficacy of the bimatoprost drug pad-intraocular lens system for OAG and OHT.Products
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System
AMA approves application in conjunction with Category I cataract surgery codes; applies to investigational bimatoprost delivery system for IOP reduction in OAG and OHT.Pipeline
SpyGlass Pharma reports long-term data on bimatoprost IOL system
Positive 36-month findings from an FIH trial and 3-month results from a phase 1/2 study support delivery of sustained IOP reduction and drop-free outcomes for OAG, OHT.Business
Leadership watch: SpyGlass, Lumata Health, and Horizon Surgical report changes
Latest news from the eyecare space includes a new VP at SpyGlass ahead of phase 3 trials on its glaucoma drug delivery platform.Pipeline
SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform
Financing to support upcoming phase 3 trials on the company’s long-term delivery system of bimatoprost for glaucoma and OHT treatment.Research
SpyGlass Pharma reports positive 18-month data on glaucoma sustained delivery system
Presented at ASCRS, new findings show promising visual outcomes and IOP lowering following sustained-release delivery of bimatoprost.Business
SpyGlass Pharma secures $90M in financing for chronic ophthalmic disease drug delivery platform
First-of-its-kind controlled-release platform is designed to significantly lower IOP.Pipeline